MEDICEXUM

The complianceadvantagein cannabis.

Medicexum is the regulatory and commercial partner for suppliers, importers and clinics building inside the UK's most scrutinised emerging market.

Send an email enquiryExplore our services

CBD. Not a controlled drug. In food and supplements it is regulated as a novel food. Same formula as THC: C21H30O2.

1,701,064

Rx items 2025

up 154%

NHSBSA FOI-03941, 30 July 2026

30,061kg

Imports 2025

up 100%

Prohibition Partners, 24 June 2026

60k to 75k

Active patients

Cannabis Industry Council, 15 May 2026

818

Products listed

up 119%

Prohibition Partners, 24 June 2026

Which licences does your operation actually need?

Four questions. An indicative regulatory stack in under a minute.

Question 1 of 4

What are you moving?

Five gates between a grow room and a UK patient.

Every one has its own regulator, licence and paperwork. We get you through each of them, in order.

1

Made to EU GMP

Cultivation and manufacture audited against the standard UK importers have to prove.

2

Home Office licence

Controlled drug licensing and an import licence for each consignment.

3

MHRA licensed importer

Wholesale dealer obligations, GDP, and a Responsible Person framework that holds up at inspection.

4

Specialist pharmacy

Supply agreements with the pharmacies that dispense unlicensed cannabis medicines.

5

Prescribed to a patient

Clinic partnerships and a product specification prescribers will choose.

Cultivators: list your products where only vetted buyers can see them.

CBPM Supply Partners is our UK market access route for licensed cultivators and extract suppliers. Once you are approved, your products, test results and stock go into a locked catalogue. Only vetted trade members can sign in, and nothing is shown to the public.

  • Trade members only, each one vetted
  • Certificates of analysis with the listings
  • Dated stock editions
Apply to list your productsSee how the route works

Trade only. Not consumer advertising and not an offer for sale. Medicexum does not procure, supply or broker cannabis based medicinal products.

A complete operating partner for cannabis based medicinal products.

All services

Regulatory compliance

MHRA, GDP and Home Office navigation. Audits, SOPs and Responsible Person frameworks.

Import and export

EU GMP compliant sourcing and licensed importation routes into the UK supply chain.

CBD and novel foods

FSA Novel Foods dossiers, public list status, labelling and reformulation for UK CBD brands.

Supply chain set up

Licence applications, storage, wholesale dealer obligations, stood up end to end.

B2B partnerships

Producers, importers and clinics matched into commercial relationships that scale.

Fixed price from £5,000

Compliance tools

Fixed scope web apps that replace compliance spreadsheets. Supplier approval, CAPA, training, batch release and product registers.

Commercial strategy

Pricing, positioning, go to market plans for new entrants and operators ready to scale.

We don't just advise on compliance systems. We build them.

Four live platforms, built-in house.

Jorja Medical Cannabis
Jorja Medical Cannabis homepage

Jorja Medical Cannabis

Clinic website and patient membership platform for a UK medical cannabis clinic.

Visit site
CBD Compliance Checker
CBD Compliance Checker homepage

CBD Compliance Checker

Free

Free novel food status check against the FSA public list.

Open tool
ClaimSafe
ClaimSafe homepage

ClaimSafe

Claim screening for UK and EU supplement brands.

Visit site
Prescription Portal
Prescription Portal homepage

Prescription Portal

Prescription writing, release and pharmacy workflow for a medical cannabis clinic. Staff access only.

Private system

Want one built for your team?

One workflow turned into a web app, or your idea turned into a working product. Fixed price from £5,000, in about 4 weeks.

See how a build worksBook a scoping call

25 years of pharmaceutical quality, applied to cannabis.

Wilson's career was built in pharmaceutical quality and validation, across GSK, Sanofi, AstraZeneca, Fujifilm Diosynth and Novartis, including commissioning, qualification and remediation programmes run to MHRA and FDA expectations. That is where the standard comes from.

He went on to lead quality and operations for a team of more than 200, and held a Global Head of Quality role inside a FTSE 100 business. Medicexum applies that standard to a market where most operators are still learning it as they go.

  • GSK
  • Sanofi
  • AstraZeneca
  • Fujifilm Diosynth
  • Novartis
  • Imperial Brands
  • RP (GDP), Cogent Skills gold standard
  • Associate, Chartered Quality Institute
  • BSc (Hons) Biotechnology
  • Lead Auditor trained (IATCA scheme)

We don't just quote the science.
We index it.

A live library of peer reviewed cannabis research, regulatory bulletins and ongoing trials, graded, tagged and updated weekly. Built for clinicians, importers and policy teams who need evidence at hand.

Evidence grading
  • Grade A128
  • Grade B155
  • Grade C154
  • Grade D63
Live, 500 studies indexed
Indexed cannabis research and regulatory bulletins
PubMedEurope PMCClinicalTrials.govNICEMHRAEMA
Grade CRegistered trial2031

Endocannabinoids in Reward

This study aims to investigate sex differences in the effects of cannabis among regular cannabis users. Participants will receive either THC or a placebo, complete questionnaires, undergo a brain scan, and provide a blood sample for genetic testing. The research focuses on understanding the impact of cannabis in individuals with Cannabis Use Disorder.

ClinicalTrials.govn=78
Grade ARCT2030

Warrior CARE: Cannabis Behavioral Health

This is a randomized, controlled clinical trial investigating the therapeutic potential of cannabinoids for treating veterans who suffer from Post Traumatic Stress Disorder (PTSD) and suicidal ideation. The study aims to evaluate the effects of cannabis on mental health conditions in a military veteran population. This trial is currently recruiting participants.

ClinicalTrials.govn=500
Grade CRegistered trial2030

Cannabis Association With Sleep Study

This study investigates the relationship between cannabis use, sleep, and stress levels. It aims to provide insights into how patterns of cannabis consumption correlate with sleep quality and stress in human participants.

ClinicalTrials.govn=60
Open the research library

Latest thinking

Regulation10 Nov 2026

Navigating AI in UK Medicinal Cannabis: MHRA's New Horizon

The MHRA's recent AI recommendations signal a pivotal shift for UK healthcare, with profound implications for medicinal cannabis. This article delves into what these changes mean for operators, from product design to regulatory submissions and future investment in an increasingly digitalised sector.

Read insight
Quality10 Nov 2026

GMP Licence Loss: The Stability Testing Wake-Up Call for UK Cannabis

A recent MHRA announcement detailing licence suspensions and revocations sends a clear message: GMP compliance, particularly around stability testing, is non-negotiable for UK medicinal cannabis operators. Boards and investors must demand robust quality systems to safeguard market access.

Read insight
CBD10 Nov 2026

FSA Novel Foods: MHRA Reform Signals New Era for CBD Compliance

The UK's regulatory landscape for CBD novel foods is perpetually shifting. A recent DHSC report detailing MHRA reforms, while primarily focused on medicinal products, carries significant, often overlooked, implications for the novel foods sector, especially concerning data requirements and safety substantiation. This confluence demands immediate attention from operators, boards, and investors.

Read insight
Read all insights

Build the UK's most compliant cannabis business, with us.

Or email contact@medicexum.co.uk